All In Biotech

Drug Trial Radar · NCT07641179

A Study to Evaluate MAR002 for Acromegaly

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR002 in Participants With Acromegaly (TROUGH-2)

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Jul 23, 2026

Primary completion

Aug 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Marea TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly

Conditions

  • Acromegaly

Interventions

  • MAR002Drug

    Subcutaneous injection

  • PlaceboDrug

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with TEAEs (treatment-emergent adverse events), SAEs (serious adverse events), and other laboratory endpointsTime frame: Baseline to Week 16
  2. Percent change from baseline in serum insulin-like growth factor 1 (IGF-1) levels as an average of Week 8 and Week 10Time frame: Baseline to Week 10

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Recruiting

  • Endocrinology Associates, Inc

    Columbus, Ohio · Recruiting

  • Consano Clinical Research

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.